Absci Corporation (ABSI) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
4.05
↑+123% vs avg
5yr avg: 1.82
30Y Low0.7·High2.5
ROE
↓
-62.5%
↑-26% vs avg
5yr avg: -49.8%
30Y Low-111%·High-33%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ABSI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Absci Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $872M | $477M | $289M | $387M | $191M | $760M | — | — |
| Enterprise Value | $857M | $463M | $258M | $330M | $154M | $527M | — | — |
| P/E Ratio → | -6.68 | — | — | — | — | — | — | — |
| P/S Ratio | 311.45 | 170.48 | 63.70 | 67.60 | 33.20 | 158.87 | — | — |
| P/B Ratio | 4.05 | 2.52 | 1.61 | 2.19 | 0.70 | 2.08 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ABSI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 165.22 | 56.84 | 57.72 | 26.76 | 110.24 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
ABSI Profitability
Margins and return-on-capital ratios measuring operating efficiency
Absci Corporation earns an operating margin of -4454.2%. Operating margins have compressed from -2020.2% to -4454.2% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -62.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -319.4% | -319.4% | -1277.6% | -731.9% | -925.0% | -832.4% | -139.5% | 100.0% |
| Operating Margin | -4454.2% | -4454.2% | -2401.6% | -2020.2% | -1857.5% | -1573.4% | -278.3% | -304.1% |
| Net Profit Margin | -4113.7% | -4113.7% | -2274.1% | -1933.6% | -1825.4% | -2111.3% | -300.3% | -319.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -62.5% | -62.5% | -58.0% | -49.1% | -32.8% | -46.6% | -111.1% | — |
| ROA | -53.6% | -53.6% | -47.9% | -41.1% | -28.1% | -39.2% | -26.6% | -33.8% |
| ROIC | -58.0% | -58.0% | -61.0% | -48.5% | -43.2% | -77.7% | — | — |
| ROCE | -65.9% | -65.9% | -58.4% | -48.3% | -31.3% | -32.0% | -28.2% | -39.1% |
ABSI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $20M exceeds total debt of $5M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.06 | 0.09 | 0.08 | 0.05 | 0.22 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.08 | -0.17 | -0.32 | -0.13 | -0.64 | -0.83 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -596.74 | -596.74 | -190.24 | -92.75 | -109.83 | -21.66 | -21.64 | -23.57 |
Net cash position: cash ($20M) exceeds total debt ($5M)
ABSI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Absci Corporation's current ratio of 6.57x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 4.08x to 6.57x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.57 | 6.57 | 4.67 | 4.08 | 6.17 | 8.07 | 7.25 | 3.94 |
| Quick Ratio | 6.57 | 6.57 | 4.67 | 4.08 | 5.68 | 7.75 | 7.25 | 3.94 |
| Cash Ratio | 6.34 | 6.34 | 3.92 | 3.30 | 5.43 | 7.46 | 6.92 | 3.78 |
| Asset Turnover | — | 0.01 | 0.02 | 0.03 | 0.02 | 0.01 | 0.05 | 0.11 |
| Inventory Turnover | — | — | — | — | 3.92 | 4.24 | — | — |
| Days Sales Outstanding | — | — | — | 139.73 | 98.44 | 108.77 | 121.72 | 39.34 |
ABSI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Absci Corporation does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $137M | $110M | $92M | $91M | $93M | $92M | $92M |
Peer Comparison
Compare ABSI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ABSIYou | $872M | -6.7 | — | — | -319.4% | -4454.2% | -62.5% | -58.0% | — |
 RXRX | $2B | -2.3 | — | — | 5.0% | -867.9% | -59.5% | -95.8% | — |
 SDGR | $962M | -9.1 | — | 77.2 | 55.7% | -65.2% | -26.3% | -39.4% | — |
 ALIT | $467M | -0.2 | 5.0 | 1.9 | 20.7% | 1.5% | -115.6% | 0.6% | 4.5 |
 TWST | $3B | -43.6 | — | — | 50.7% | -36.2% | -16.4% | -26.9% | — |
 BEAM | $3B | -35.7 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 NTLA | $2B | -3.5 | — | — | — | — | -53.5% | — | — |
 CRSP | $5B | -8.1 | — | — | -2642.3% | -18933.6% | -30.2% | -27.4% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.7 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $173B | 26.3 | 18.8 | 27.6 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 CDNA | $1B | -51.8 | — | 29.6 | 67.0% | -5.5% | -6.3% | -5.7% | — |
| Healthcare Median | — | 22.2 | 14.0 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See ABSI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABSI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ABSI vs RXRX
Side-by-side business, growth, and profitability comparison vs Recursion Pharmaceuticals, Inc..
Start ComparisonABSI — Frequently Asked Questions
Quick answers to the most common questions about buying ABSI stock.
What is Absci Corporation's P/E ratio?
Absci Corporation's current P/E ratio is -6.7x. This places it at the 50th percentile of its historical range.
What is Absci Corporation's ROE?
Absci Corporation's return on equity (ROE) is -62.5%. The historical average is -60.0%.
Is ABSI stock overvalued?
Based on historical data, Absci Corporation is trading at a P/E of -6.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Absci Corporation's profit margins?
Absci Corporation has -319.4% gross margin and -4454.2% operating margin.